1 / 76

Gregory Ducrocq Cardiology D epartement Bichat Hospital Paris, France

Management of STEMI patients How to implement ESC guidelines. Gregory Ducrocq Cardiology D epartement Bichat Hospital Paris, France. What is the purpose of guidelines?. A l egal document? Something to follow in any case? Something to learn by heart ?.

aldis
Download Presentation

Gregory Ducrocq Cardiology D epartement Bichat Hospital Paris, France

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Management of STEMI patients How to implement ESC guidelines Gregory Ducrocq CardiologyDepartement Bichat Hospital Paris, France

  2. Whatis the purpose of guidelines? A legal document? Something to follow in any case? Something to learn by heart?

  3. « Guidelines summarize and evaluate all availableevidence » « guidelines are not substitutes but are complements for textbooks » « The guidelines do not howeveroverride the responsability of healthprofessionals to makeappropriatedecisionsaccording to the circumstances of individual patient » ESC STEMI guidelines.

  4. A summary of availableevidencethatyoushouldimplementaccording to your local conditions

  5. How are the guidelines built?

  6. Guidelines are not a monolith Still a lot of lowlevelrecommendations A majority of lowlevel of evidence There is room for local interpretation and implementationaccording to your local practice

  7. Guidelines Implementation Emergency care Antithrombotictherapy Post discharge

  8. A preciseanalysis of local conditions iskey for guidelines implementation

  9. Guidelines Implementation Emergency care Antithrombotictherapy Post discharge

  10. How do weimplement in France? A network of physician-staffed Mobile Intensive Care Units

  11. What are the results?

  12. Reperfusion therapy in STEMI FAST MI 2010 registry

  13. STEMI: reperfusion therapy IV lysis: 57% prehospital FAST MI 2010 registry

  14. Meeting the ESC requirements of the guidelines influences survival Median time from ECG to PCI: 110 min [78; 185] Only 55% met the recommended timelines Adjusted OR: 2.92 (1.17-7.30) P=0.02 FAST MI 2010 registry

  15. A preciseanalysis of local conditions iskey for guidelines implementation

  16. Implementationaccording to your local conditions? How many PCI capable centers? Which volume? How distant are they? Experience of operators in primary PCI Financial issues: canany patient betreated by primary PCI? Transfer: do you have doctors in the ambulances?

  17. Guidelines Implementation Emergency care Antithrombotictherapy Post discharge

  18. What do the trials say?

  19. Clopidogrel on top of ASA in STEMI 11 10 9 8 7 6 5 4 3 2 1 0 0 7 14 21 28 CLARITY (TIMI 28) COMMIT (CCS-2) N=45,852; 50% lytic,75 mg/day x 16 days N=3491; 75 y/o, lytic, 300 mg load, 75 mg/day, cath in 2-8 days Placebo + ASA: 2310 events (10.1%) 15 Placebo Clopidogrel + ASA 2121 events (9.2%) Clopidogrel 10 Proportion with End Point, % 5 9% proportional risk reduction (P=0.002) Odds ratio 0.80 (95% CI 0.65-0.97) P=0.026 0 0 5 10 15 20 25 30 Day (Up to 28 Days) Day (CV death, recurrent MI, recurrent ischemia) (Death, reinfarction, stroke) Sabatine et al. N Engl J Med.2005 COMMIT Collaborative Group Lancet.2005

  20. Clopidogrel non responders Number of patients 112 104 96 n=544 88 80 72 64 56 48 40 32 24 16 8 0 < -20 [-10,0] [11,20] [31,40] [51,60] [71,80] [91,100] Delta 5µM ADP AdaptedfromSerebruany et al. JACC2005

  21. Prasugrel New oral antiplatelet agents can achieve faster and stronger platelet inhibition Ticagrelor Brandt et al Am Heart J 2007 Gurbelet al Circulation2009

  22. TRITON: Prasugrelvsclopidogrel in ACS 15 138 events Clopidogrel HR 0.81(0.73-0.90)P=0.0004 12.1 CV Death / MI / Stroke 9.9 10 NNT = 46 Prasugrel Endpoint (%) 5 35 events TIMI Major NonCABG Bleeds Prasugrel 2.4 HR 1.32(1.03-1.68)P=0.03 1.8 Clopidogrel 0 NNH = 167 0 30 60 90 180 270 360 450 Days Wiviott S et al NEJM 2007

  23. PLATO: ticagrelor vs clopidogrel in ACS Primary endpoint time to CV death, MI or stroke 13 12 11.7 Clopidogrel 11 10 9.8 9 Ticagrelor 8 7 Cumulative incidence (%) 6 5 4 3 2 HR 0.84 (95% CI 0.77–0.92), p=0.0003 1 0 0 60 120 180 240 300 360 Days after randomisation No. at risk Ticagrelor 9,333 8,628 8,460 8,219 6,743 5,161 4,147 Clopidogrel 9,291 8,521 8,362 8,124 6,743 5,096 4,047 Wallentin et al NEJM 2009

  24. Time to major bleeding – primary safety event 15 Ticagrelor 11.58 11.20 10 Clopidogrel K-M estimated rate (% per year) 5 HR 1.04 (95% CI 0.95–1.13), p=0.434 0 0 60 120 180 240 300 360 Days from first IP dose No. at risk Ticagrelor 9,235 7,246 6,826 6,545 5,129 3,783 3,433 Clopidogrel 9,186 7,305 6,930 6,670 5,209 3,841 3,479

  25. 7 6 Clopidogrel (300 or 600) 5.1 5 4.0 4 Ticagrelor Cumulative incidence (%) 3 2 1 HR 0.79 (95% CI 0.69–0.91), p=0.001 0 0 60 120 180 240 300 360 Days after randomisation 9,333 8,294 8,822 8,626 7119 5,482 4,419 9,291 8,865 8,780 8,589 7079 5,441 4,364 Cardiovascular death over time Wallentin et al NEJM 2009

  26. Prasugrel or ticagrelor in STEMI patients?

  27. Antithrombotictherapy: What do the Guidelines say?

  28. Prasugrel in ACS Pro • Efficacybenefit • 1 / day • Possible greaterefficacy and safety in diabetic patients Against • No cross over withclopidogrel • Cost • Restrictions • < 65 kg • > 75 yo • Previous stroke

  29. Ticagrelor in ACS Pro • Efficacybenefit • Mortalitybenefit • Simplification (relative) • Reversibility (relative) Against • Bid • Extra-platelet effects • Bradycardia • Dyspnea • Cost

  30. Prasugrel vs. Ticagrelor: Weighingpros and cons in orderto buildyourownalgorithm As simple as possible!

  31. Which anticoagulant in primary PCI?

  32. Antithromboticsin STEMI The Bichat formulary STEMI – Primary PCI • Aspirine • Load 500 mg • Maintenance 75 mg/j • Ticagrelor • Load 180 mg • Maintenance 90 mg bid • Bivalirudin(prolonged 4 h post PCI) • Abciximab for bailout If bleedingrisk or CI to ticagrelor or association to OAC: Clopidogrel 600/75

  33. Guidelines Implementation Emergency care Antithrombotictherapy Post discharge

  34. Impact of combinedsecondarypreventiontherapyaftermyocardialinfarction in USIC 2000 Danchin N et al. Am Heart J 2005

  35. How to implement?

More Related